News | April 07, 2025
Fluor to provide EPCM services for pharmaceutical facility in Indiana
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
According to IQVIA sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market achieved annual sales of approximately $39.3 mn
L-HPC was independently developed by Shin-Etsu Chemical as a disintegrant for tablets
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
This expanded partnership helps Evonik to streamline its distribution model in Asia Pacific
Havix was incorporated under the laws of the State of Delaware on February 17, 2015
USFDA inspection at Alembic Pharma's Bioequivalence facility
Subscribe To Our Newsletter & Stay Updated
